ArticleInternational journal of molecular sciences2026
Synthetic Curcuminoids Combined with Blue-Light-Mediated Photodynamic Therapy for Anti-Inflammatory Effect and Potential Mechanism on Imiquimod-Induced Psoriasis-like Proliferation of Keratinocytes.
Article in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Psoriasis is characterized by the rapid proliferation of keratinocytes, leading to erythematous plaques with silvery scales, skin pain, and impaired quality of life. Photodynamic therapy (PDT) has emerged as a promising treatment modality for various skin disorders, including psoriasis. Curcumin, a natural photosensitizer, possesses potent anti-inflammatory and antioxidant properties. In this study, we investigated the anti-inflammatory potential of synthetic curcuminoids combined with blue-light-mediated PDT for psoriasis treatment using human keratinocyte (HaCaT) cells. MTT assays demonstrated that the synthetic curcuminoids (1E,6E)-1,7-bis(5-methylthiophen-2-yl)hepta-1,6-diene-3,5-dione (No. 11) and (1E,6E)-1,7-di(thiophen-2-yl)hepta-1,6-diene-3,5-dione (No. 12) exhibited minimal cytotoxicity toward HaCaT cells. Upon ultraviolet-visible light irradiation, curcuminoid-treated cells generated intracellular reactive oxygen species, confirming the photodynamic activity induced by blue light exposure. Treatment with synthetic curcuminoids significantly suppressed the secretion of pro-inflammatory cytokines IL-17A/F and IL-8 in imiquimod-stimulated HaCaT cells, a commonly used psoriasis-like inflammatory model, indicating notable anti-inflammatory effects. Western blot analysis further revealed an increased Bax/Bcl-2 ratio in cells treated with synthetic curcuminoids No. 11 or No. 12 under photodynamic irradiation, suggesting the induction of apoptosis. Synthetic curcuminoids combined with blue-light PDT may represent a promising and cost-effective strategy for psoriasis.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.